- Home
- ARMP vs CALC Comparison
ARMP vs CALC Comparison
Compare ARMP & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- CALC
- Stock Information
- Founded
- ARMP N/A
- CALC 2011
- Country
- ARMP United States
- CALC United States
- Employees
- ARMP N/A
- CALC N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- CALC Health Care
- Exchange
- ARMP Nasdaq
- CALC Nasdaq
- Market Cap
- ARMP 52.1M
- CALC 48.1M
- IPO Year
- ARMP N/A
- CALC N/A
- Fundamental
- Price
- ARMP $2.54
- CALC $2.94
- Analyst Decision
- ARMP Strong Buy
- CALC Strong Buy
- Analyst Count
- ARMP 1
- CALC 2
- Target Price
- ARMP $9.00
- CALC $14.50
- AVG Volume (30 Days)
- ARMP 13.2K
- CALC 145.0K
- Earning Date
- ARMP 08-12-2025
- CALC 08-11-2025
- Dividend Yield
- ARMP N/A
- CALC N/A
- EPS Growth
- ARMP N/A
- CALC N/A
- EPS
- ARMP N/A
- CALC N/A
- Revenue
- ARMP $4,699,000.00
- CALC N/A
- Revenue This Year
- ARMP $8.43
- CALC N/A
- Revenue Next Year
- ARMP N/A
- CALC N/A
- P/E Ratio
- ARMP N/A
- CALC N/A
- Revenue Growth
- ARMP 14.24
- CALC N/A
- 52 Week Low
- ARMP $0.90
- CALC $1.42
- 52 Week High
- ARMP $2.96
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- ARMP 65.04
- CALC 52.55
- Support Level
- ARMP $2.14
- CALC $3.37
- Resistance Level
- ARMP $2.61
- CALC $4.26
- Average True Range (ATR)
- ARMP 0.14
- CALC 0.48
- MACD
- ARMP -0.00
- CALC -0.01
- Stochastic Oscillator
- ARMP 81.08
- CALC 41.59
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.